News
Gefurulimab met all primary and secondary endpoints in the Phase III PREVAIL trial in patients with gMG, run by pharma giant AstraZeneca.
Positive topline results of Apnimed's LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.
Windward Bio has launched the Phase II POLARIS trial of the recombinant, fully human monoclonal antibody, WIN378, in individuals with asthma.
The trail demonstrates that a swallowable, low-pill, non-absorbed iron polymer can match or exceed sevelamer in phosphate control.
ANI Pharmaceuticals has disclosed the outcomes of its NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results